Target
RAC-alpha serine/threonine-protein kinase
Ligand
BDBM50398376
Substrate
n/a
Meas. Tech.
ChEMBL_875897 (CHEMBL2187635)
IC50
12±n/a nM
Citation
 Blake, JFXu, RBencsik, JRXiao, DKallan, NCSchlachter, SMitchell, ISSpencer, KLBanka, ALWallace, EMGloor, SLMartinson, MWoessner, RDVigers, GPBrandhuber, BJLiang, JSafina, BSLi, JZhang, BChabot, CDo, SLee, LOeh, JSampath, DLee, BBLin, KLiederer, BMSkelton, NJ Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem 55:8110-27 (2012) [PubMed]  Article 
Target
Name:
RAC-alpha serine/threonine-protein kinase
Synonyms:
AKT phosphorylation (p-AKT) | AKT1 | AKT1/PPP1CA | AKT1_HUMAN | C-AKT | PKB | PKB alpha | Protein kinase Akt-1 | Protein kinase B | Protein kinase B (AKT1) | Protein kinase B (Akt 1) | Protein kinase B (Akt) | Protein kinase B alpha | Protein kinase B alpha (AKT1) | Proto-oncogene Akt (Akt1) | Proto-oncogene c-Akt (AKT) | Proto-oncogene c-Akt (AKT1) | RAC | RAC-PK-alpha | RAC-alpha serine/threonine-protein kinase (AKT) | RAC-alpha serine/threonine-protein kinase (AKT1) | RAC-alpha serine/threonine-protein kinase (pAKT)
Type:
Enzyme
Mol. Mass.:
55681.25
Organism:
Homo sapiens (Human)
Description:
P31749
Residue:
480
Sequence:
MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
  
Inhibitor
Name:
BDBM50398376
Synonyms:
CHEMBL2177382
Type:
Small organic molecule
Emp. Form.:
C24H31ClFN5O
Mol. Mass.:
459.987
SMILES:
CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](F)C[C@@H](C)c12)c1ccc(Cl)cc1 |r|
Structure:
Search PDB for entries with ligand similarity: